Literature DB >> 3141057

The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.

K Sakamoto1, H Nakajima, J Shimizu, T Katagiri, C Kiyotaki, H Fujiwara, T Hamaoka.   

Abstract

The present study investigated the role of antigen-presenting cells (APC) in the activation of noncytolytic T cells against tumor antigens. The noncytolytic-type T cells exerted their antitumor effect by producing gamma-interferon (IFN-gamma) and by activating macrophages as the ultimate effectors. The production of IFN-gamma by these noncytolytic T cells following the stimulation with tumor cells required the participation of Ia+ APC, since the depletion of APC from cultures of tumor-immunized spleen cells resulted in almost complete inhibition of the IFN-gamma production. Both L3T4+ and Lyt-2+ subsets of T cells were capable of producing IFN-gamma, and the requirement of APC for the production of IFN-gamma was the case irrespective of whether noncytolytic T cells were of L3T4+ or Lyt-2+ phenotype. More importantly, it was demonstrated that the production of IFN-gamma by L3T4+ and Lyt-2+ T cells was inhibited by addition of the respective anti-class II and anti-class I H-2 antibody to cultures. These results indicate that antitumor L3T4+ or Lyt-2+ noncytolytic T cells are activated for the IFN-gamma production by recognizing tumor antigens in the context of self-class II or -class I H-2 molecules on APC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141057     DOI: 10.1007/bf00205449

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.

Authors:  K Sakamoto; H Fujiwara; H Nakajima; T Yoshioka; Y Takai; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1986-11

2.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

Authors:  D E Kern; J P Klarnet; M C Jensen; P D Greenberg
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

3.  The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.

Authors:  H Fujiwara; Y Takai; K Sakamoto; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

4.  Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens.

Authors:  V T Oi; P P Jones; J W Goding; L A Herzenberg; L A Herzenberg
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

5.  The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.

Authors:  A Kosugi; T Yoshioka; T Suda; H Sano; Y Takahama; H Fujiwara; T Hamaoka
Journal:  J Leukoc Biol       Date:  1987-12       Impact factor: 4.962

6.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.

Authors:  H Nakajima; H Fujiwara; Y Takai; Y Izumi; S Sano; T Tsuchida; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

7.  Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens.

Authors:  K Ozato; N Mayer; D H Sachs
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

8.  Both L3T4+ and Lyt-2+ helper T cells initiate cytotoxic T lymphocyte responses against allogenic major histocompatibility antigens but not against trinitrophenyl-modified self.

Authors:  T Mizuochi; H Golding; A S Rosenberg; L H Glimcher; T R Malek; A Singer
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

9.  Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection.

Authors:  A S Rosenberg; T Mizuochi; S O Sharrow; A Singer
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

10.  Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.

Authors:  K Sakamoto; T Yoshioka; J Shimizu; S Sato; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1988-01
View more
  3 in total

1.  Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells.

Authors:  J P Zou; J Shimizu; K Ikegame; H Takiuchi; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Tumor-specific T cell lines: capacity to proliferate and produce interleukin 2 in response to various forms of tumor antigens.

Authors:  J Shimizu; T Suda; T Katagiri; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1992-02

3.  Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.

Authors:  X F Li; H Takiuchi; J P Zou; T Katagiri; N Yamamoto; T Nagata; S Ono; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1993-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.